Wed, January 11, 2023
Tue, January 10, 2023
Mon, January 9, 2023
Sun, January 8, 2023
Fri, January 6, 2023
Thu, January 5, 2023

Thomas Smith Maintained (VRDN) at Buy with Increased Target to $45 on, Jan 9th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-increased-target-to-45-on-jan-9th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Thomas Smith of SVB Leerink, Maintained "Viridian Therapeutics, Inc." (VRDN) at Buy with Increased Target from $40 to $45 on, Jan 9th, 2023.

Thomas has made no other calls on VRDN in the last 4 months.



There are 4 other peers that have a rating on VRDN. Out of the 4 peers that are also analyzing VRDN, 0 agree with Thomas's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Thomas


  • Serge Belanger of "Needham" Initiated at Strong Buy and Held Target at $45 on, Monday, December 19th, 2022
  • Tiago Fauth of "Credit Suisse" Initiated at Buy and Held Target at $51 on, Friday, December 16th, 2022
  • Douglas Tsao of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $35 on, Thursday, December 1st, 2022
  • Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $46 on, Tuesday, November 15th, 2022

Publication Contributing Sources